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Abstract

Two medication formulations are compared using noncompartmental pharmacokinetic (PK)
variables. However, more than the ratio of mean effects is of interest. A difference in
formulation coeficients of varication (CV), within- or between-subject, is sought. The
experimental design chosen is a 2 sequence crossover design of the form ABBA and BAAB,
where A and B are two medication formulations. A mixed linear model is defined that contains
random effects for subjects and for subject by formulation interactions. The model has fixed
effects for the average formulation effects and period effects. The 2 formulations are assumed to
have different error terms. The average formulation effect ratios and within-subject CVs may be
compared by usual methods. An approximate Z-statistic is computed to compare the betweensubject CV s. This statistic assumes a correlation of the 2 between-subject CV estimates. In
addition, a tractable variance ratio is defined to indicate the extent to which the average effects
ratio is applicable to each subject.
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1. Introduction
In testing for bioequivalence, the focus is usually on showing that the average areas under the
blood level curve (AUe) of two formulations differ by no more than 20%. Little attention is
given to the variability of the AUe. Usually variances are assumed to be equal. It is also
standard practice to use a crossover design because crossover designs require fewer subjects and
carryover effects have not been a major problem in bioequivalence studies.

If, however, the original formulation has shown a large within- and between-subject variability, it
might be of interest to see if the new formulation might not produce a smaller variation. Thus,
the estimation and testing of variances can be of as much interest as can be the mean effects.
A second assumption usually made is that the average bioequivalence is applicable to each and
every patient who takes the drug. That is, it is assumed that the test formulation cannot be >20%
more bioavailable in one patient while the standard formulation is >20% more bioavailable in a
second patient.
We have data from a 4-period, 2-sequence crossover design of the form ABBA and BAAB,
where A and B are two medication formulations. We are interested in estimating and testing the
between-subject variance component, the within-subject variance component, the average
bioavailability and to provide some kind of assessment of the extent to which the average
bioavailability is applicable to each and every patient. This was also a compound for which the
standard formulation had shown both a large within- and between-subject variance components
in previous pharmacokinetic studies.
Most of what was requested was fairly straight forward. However, the testing of the betweensubject variance component presented a challenge. Most linear models for this kind of a design
assume a constant between-subject variance component called, "the subject effect." Since the
design is a crossover, any two estimates of the between-subject variance components are
correlated. In most tests for variance components, the components are assumed to be
independent and this cannot hold if 2 different between-subject variance components are
estimated from the same subjects.
A second challenge was posed by determining how to best define an index of the degree to which
the average bioavailability is applicable to each patient.
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2. Variance Component Analysis of PK Parameters
Let treatment A be a capsule and treatment B be a tablet. Each subject received 2 treatments in 4
different periods depending on his assigned treatment sequence. A subject assigned to sequence
1 received A, B, B, A at period 1,2,3,4, respectively. A sequence 2 subject received B, A, A,
B.
Let
S - N(O, 0/) be the subject effect,
TSA - N(O, OA2) be the treatment A by subject interaction,
TSB - N(O, OBZ) be the treatment B by subject interaction,
ESi - N(O, 0/) be the within-subject error for treatment A,
l1si - N(O, 0I1Z) be the within-subject error for treatment B.
Then, for a subject in sequence ABBA, the linear models for the observation on each subject at
each period can be written as follows:
periodl:
period2:
period3:
period4:

YSll =
YS12=
YS13=
YSI4=

11
11
11
11

+ S + TSA + 1'A + TI j + ESj '
+ S + TSB + 1'B + TIz + l1sl'
+ S + TSB + 1'B + TI3 + l1sz,
+ S + TSA + 1'A + TI4 + ES2'

Similarly for a subject in sequence BAAB, the linear models can be written as follows for each
period.
period! :
period2:
period3:
period4:

YSZI = 11 + S + TSB + 1'B + TIl + l1sl'
Yszz= 11 + S + TSA + 1'A + TIz + ESI '
YSZ3= 11 + S + TSA + 1'A + TI3 + ES2'
YS24 = 11 + S + TSB + 1'B + TI4 + l1sz·

In the models above, 11, 1'A' 1'B' TIl' TI z, TI 3, and TI4 are fixed effects. These denote the intercept,
fixed treatment effects and fixed period effects. It is assumed that NI subjects are assigned to
sequence 1 and N z subjects are assigned to sequence 2 and N = N j + N 2.
Note that the fixed period effects could be made sequence dependent without changing the
results which follow.
For sequence ABBA, let
ZSI = (YSll + YS14)/2 = 11 + S + TSA + 1'A + (TIl + TI 4)/2 + (Esl + Ed/2 ,
Zsz = (YSIZ + YS13)/2 = 11 + S + TSB + 1'B + (TI 2 + TI 3)/2 + (l1s1 + lldl2,
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=(YSll - YSI4)12 =eltl - TI4)12 + (ESI - ES2)/2,
= (YS12 - YS13)/2 = (TI 2 - TI 3)/2 + (11s1 -11s2)12,

for S=1, ... , N 1•
Similarly, for sequence BAAB, let
W SI = (YS22 + YS23)12 = f-l + S + TSA + 't"A + (TI 2 + TI3)/2 + (ESI + EsI )/2,
W S2 = (YS21 + YS24)/2 = f-l + S + TSB + 't"B + (TIl + TI4)12 + (11s1 + 11sl)l2,
WS3 = (YS22 - YS23)12 = (TI 2 - TI 3)12 + (Esl - EsI )I2,
W S4 (YS21 - YS24)12 (TIl - TI4)12 + (11s1 -11sl)l2·
for S = NI +1, ... , NI + N 2.

=

=

Let Zs= (ZSI' ZS2' ZS3' ZS4)', then the random vectors Zs' S=1, ... , N have
't"A +( TIl +TI4 )/2
't" B +( TI2 +TI 3 )/2
(TI! -TI 4)12
(TI 2-TI 3 )/2

and covariance matrix
2

2

2

2

(JS+(JA +(Ji2

2

(Js

2

2

2

0

0
0

(Js

(JS+(JB+(JTJ 12

0

0

0

(Ji2

0

0

0

0

(JTJ/2

Cov(Zs)

2

2

Similarly, let Ws= (WSJ ' W S2 ' W S3 ' W S4)" then the random vectors W s , S = N J +1, ... , N] + N2
have different means but the same covariance matrix as Zs, S=1, ... , N.
Let
A

=

L

(Zs-Z)(Zs-Z)/,

seq=!
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where

By Corollary 7.2.1 of Anderson (1958), A is a Wishart Matrix with df = N 1 -1 and B is also a
Wishart Matrix with df =N2 -1.
Let C = A + B = (C i)4x4 and denote I = (aij )4x4 = Cov(Zs). Then by Theorem 7.3. of Anderson
(1958), C is a Wishart Matrix with degree of freedom n = N-2 and covariance matrix I. That is,

C - W(I. n).

B(D) = n [(a S
2 +A
a 2 + a € 2/2) - (a S2 + a B2 + a 1] 2/2 )- a € 2/2 + a 1] 2/2 ] = n(a A2 - a B
2)' and

2
Since Var(C.)
11 = 2na.11 and Cov(C.
11' C·)
JJ
(1958), and the estimates of aij are

2
= n(a··a·
1J 1J + a··a··)
1J 1J = 2na·1J by page 161 of Anderson

Cij

n

We have

If a/ = a B2 , then the between-subject variance components a/ + a/ and a B2 + a s2 are
respectively equal as well.
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Let

z

e(D)
Var(D)

D is a linear combination of dependent X2 variable. Thus, an approximate z-statistic will be used
to derive p-values for the test ofHo: OA 2 = 0B2. Hence, the p-value for testing the between-subject
variability is
p = 2(1 - 'P(Z)),
where 'P is the standard normal distribution function.
The p-value for testing the within-subject variability (Ho:

F

=

°EA2

0/ = OfJ2) is from a F-test.

Let

C2
33

then F - F(n, n). Hence the within-subject p-value is
p = F(n, n) (r),
where r = max(F, IfF).
Since OS2 + OA2 =(OS2 + OA2 + 0/12) - 0/12 = Oil - 0 33 is the between-subject variance component
for Treatment A, 0/ + OA2 may be estimated by (C II - C33 )/n. Similarly, the between-subject
variance component for Treatment B may be estimated by (C 22 - C44 )/n.
The within-subject variance for Treatment A is estimated by 2C 3/n, and the within-subject
variance for Treatment B is estimated by 2C4in.
If it is desired to estimate the coefficient of variation of the variance components, the problem
may be simplified by taking the natural log of each value and compute variance components of
transformed values. The square root of variance components when multiplied by 100 yield an
estimate of the corresponding coefficients of variation of the untransformed values. That is
100~Var(lnX)

::=

SD
100_x.
~x
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3. Evaluation of Individual Bioequivalence
It was further desired to determine whether the average effect of the treatments may be applied to
the population as a whole or whether each subject had his own unique difference between the
treatments. If OA2 = OB2 = 0 and 0 / = 0T]2 then the treatment effect difference "C A - "C B was equally
valid for each individual subject.

Define
DTC = ZSI - ZS2 for sequence 1, and
DTC =W SI - W S2 for sequence 2.
Then
E(DTC) = "C A - "C B + (1t 1 - 1t2 - 1t3 + 1t4 )12, for sequence 1 subjects, and
E(DTC) = "C A - "C B - (1t I - 1t2 - 1t3 + 1t 4 )12, for sequence 2 subjects, and
Var(DTd = OA2 + OB2 +0/12 + 0T]212, for both sequences.
Remember that treatment A was a Capsule and B was a Tablet.
Furthermore, define
Dcc = 2ZS3 for sequence 1, and
Dcc = 2WS3 for sequence 2.
Then

E(Dcd =1t1 - 1t 4 , for sequence 1 subjects, and
E(Dcd =1t2 - 1t 3 , for sequence 2 subjects, and
Var(Dcd = 0/, for both sequences.

Furthermore, define

Then r = 1 when 0 / = OB2 = 0 and 0€2 = 0T]2. The parameter maybe used as an index of the extent
to which average difference between the capsule and the tablet may be applied to individual
subjects. Values of r closed to 1 indicate good applicability of the population average difference
to individual subjects. Large values of r indicate that each patient has his own rule.
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Let

where

1"
- (Z)
- - ~ D Te ' D Te
Nl -1 seq=l

- (1)

DTe

_1-L
N

z -1 seq=Z

DTC'

and

SSwithin

=

"

- (I) Z

"

- (Z) Z

~ (Dec-Dec) + ~ (Dec-Dec)

seq=l

.

seq=Z

Then
and

Let

R

2SSbet
SSwithin

Then,
Rlr - F(n, n).
Since Pre Rlr> F(n,n)(0.05)) = 0.95, the upper 95% confidence limit for r can be calculated by
RIF(n, n)(0.05).
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4. Examples
To illustrate our approach, 4 samples were randomly generated using the model described in
Chapter 2. Each sample was generated using a different set of parameters. There are 24 subjects
in a group, 12 in each sequence. The data was log transformed before analysis. Tables 1 and 2
give the variance component estimates and p-values from different set of parameters. Table 3
gives the test results for individual bioequivalence. The STD of the transformed data is
essentially the CY of the original data. For a subject, the interclass correlation is calculated as

In the first sample, the parameters are set as follows:
as = 0.30, a A = 0, aB = 0.40, a€ = 0.05, and aT) = 0.10. Therefore the interclass correlation =
0.58.
The within-subject %CY for tablet = 100xaT) =10. The within-subject %CY for capsule =
100xa€ = 5. The estimates for the %CY are 11.25 and 5.46 respectively. It turn out that the pvalue for testing the equality of the two %CY is 0.001 (Table 1). In this sample, the betweensubject %CY for tablet = 100x(a/ + a B 2y/2 = 50, and the between-subject %CY for capsule =
100x(as2 + aA2)'h = 30, The estimates for the %CY are 47.31 and 29.55 respectively. P-value for
testing the equality of the two %CY is 0.035 (Table 2).
Also from this sample, the individual bioequivalence index r = 66.50. Its estimate is 49.16 and
the p-value for testing r = 1 is <0.001 (Table 3).
As seen from Tables 1,2 and 3, for all these four samples the test essentially give the correct
conclusion.
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Table 1. Within-subject variability of pharmacokinetic parameters by formulation
Sample
1
2
3
4

Information
Parameters
Estimates
Parameters
Estimates
Parameters
Estimates
Parameters
Estimates

Interclass
Correlation
0.580
0.364
0.900
0.500

Tablet
Within %CV
10
11.25
30
33.75
10
11.25
10
11.25

Capsule
Within %CV
5
5.46
30
32.76
10
10.92
10
10.92

P-Value
Within
0.001
0.889
0.889
0.889

Table 2. Between-subject variability of pharmacokinetic parameters by formulation

Sample
1
2
3
4

Information
Parameters
Estimates
Parameters
Estimates
Parameters
Estimates
Parameters
Estimates

Interclass
Correlation
0.580
0.364
0.900
0.500

Tablet
Between %CV
50
47.31
50
46.34
30
29.39
30
28.50

Capsule
Between %CV
30
29.55
30
25.63
30
29.43
30
28.06

P-Value
Between
0.035
0.077
0.986
0.940

Table 3. Analysis of individual bioequivalence between formulation

Sample

Interclass
Correlation

1
2
3
4

0.580
0.364
0.900
0.500

Population
Individual
Bioequivalence
Index
66.50
2.78
1.00
9.00
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Sample
Individual
Bioequivalence
Index
49.16
1.98
0.73
8.13

95% Upper
Confidence
Band for
Index
100.7
4.06
1.49
16.65

P-Value for
Testing
Different
from 1
<0.001
0.058
0.769
<0.001
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5. Summary
In order to compare within- and between-subject variance components in a cross-over design, it
is necessary to define a new mixed linear model for a pharmacokinetic crossover trial. Terms
have to be added to the model for the subject by treatment interaction for each dosage form
investigated. Error terms in the model also have to differ between dosage forms.
Comparisons of means and within-subject variance components may be done in a straight
forward manner. A test of the difference between the between-subject components is developed
using a Z-test and an estimate of the covariance of the between-subject variance components.
The size of the variance of the within-subject, between treatment difference relative to the
variance of the within-subject, within standard dosage form difference provides an index of the
extent of the appropriateness of using the population average relative bioavailability as a measure
of each individual subject's relative bioavailability. This index provides a measure of the
relative size of the subject by treatment interactions. It also has a scaled F-distribution which is
very easy to work with in applications.
Examples presented show that in cases where the size of within- and between-subject CV may be
of concern, differences can be found with moderate size samples. Examples presented also show
that it may be possible to have equal between and within-subject CV's for 2 dosage forms, but at
the same time the use of the average bioavailability is inappropriate because the subject by
dosage form interactions are relatively large compared to the within-subject CV.
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